Latest filingSep 02, 2026Most recent Form 4
AMLX
Amylyx Pharmaceuticals, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$00 sells
Net open-market+$06 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period8transactions
- A · Grants / awards · dominant5 · 63%
- M · Option exercise3 · 38%
Activity by reported role
A joint filing can contribute to multiple roles8transactions
- Director · dominant3 · 38%
- Chief executive officer2 · 25%
- Chief financial officer1 · 13%
- CLO1 · 13%
- CMO1 · 13%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (6)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeFirestone KarenCommon Stock · Direct
91,900Aug 31, 2026
Cohen Joshua BCommon Stock · Direct
3,643,587Aug 18, 2026
Bedrosian Camille LCommon Stock · Direct
288,092Aug 18, 2026
Mazzariello GinaCommon Stock · Direct
200,374Aug 18, 2026
Klee Justin B.Common Stock · Direct
3,643,520Aug 18, 2026
Frates James MCommon Stock · Direct
244,435Aug 18, 2026
Firestone KarenStock Option (right to buy) · Direct
0Aug 31, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- FK+$170.3k
- FM+$0
- KB+$0
- MG+$0
- BL+$0
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
AMLX transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| AMLX | Firestone Karen | DIR | exercise | 25.0k | $0 | M | — | 0.0% | 09/02 | 08/31 |
| AMLX | Firestone Karen | DIR | exercise | 25.0k | $12.6M | M | — | 0.0% | 09/02 | 08/31 |
| AMLX | Firestone Karen | DIR | exercise | 25.0k | $4.40M | M | — | 0.0% | 09/02 | 08/31 |
| AMLX | FRATES JAMES M | CFO | grant | 22.8k | $0 | A | −12.5% | 08/21 | 08/18 | |
| AMLX | Klee Justin B. | CEO | grant | 60.0k | $0 | A | −12.5% | 08/21 | 08/18 | |
| AMLX | Mazzariello Gina | CLO | grant | 21.2k | $0 | A | −12.5% | 08/21 | 08/18 | |
| AMLX | Bedrosian Camille L | CMO | grant | 22.8k | $0 | A | −12.5% | 08/21 | 08/18 | |
| AMLX | Cohen Joshua B | CEO | grant | 60.0k | $0 | A | −12.5% | 08/21 | 08/18 |
Amylyx Pharmaceuticals, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Amylyx Pharmaceuticals, Inc.?
Firestone Karen, FRATES JAMES M, Klee Justin B., Mazzariello Gina, Bedrosian Camille L, Cohen Joshua B.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
No code-P purchases or code-S sales were reported in the selected period.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.